View Activities

CPD 2: Risky Business - Screening Patients for Substance Use Disorder

Activity Details
  • Credit Amounts:
    • CME: 1.25
    • CPE: 1.25
    • Other: 1.25
    • ASWB ACE: 1.25
    • CNE: 1.25
  • Cost: Free
  • Release: Jan 17, 2024
  • Expires: Jan 17, 2027
  • Estimated Time to Complete:
    1 Hour(s)  15 Minutes
  • Average User Rating:
    (15 Ratings)

Faculty

Julie B.  Perry Julie B. Perry, DNP
Director Medical/Clinical Practice
Bluegrass Community Health Center
Lexington, Kentucky

Psychiatric Mental Health/Family Nurse Practitioner
Eastern State Hospital/Central Kentucky Recovery Center Managed by University of Kentucky
Lexington, Kentucky


Needs Statement

According to the Substance Use Mental Health Service Administration (SAMHSA) nearly 80% of people with an opiate use disorder do not receive treatment. Because of this more healthcare providers need to screen for substance use disorders including opiate use disorder and provide or refer to appropriate treatment.

Target Audience

Healthcare professionals in a primary care setting.

Objectives

Upon completion of this educational activity, you will be able to:
1. Explain why screening for substance use disorder and link to treatment are needed in primary care
2. Discuss steps of SBIRT for screening
3. Compare validated screening tools for substance use including AUDIT, DAST, CRAFT, ASSIST
4. Identify patients with substance use disorder according to DSM-V Criteria
5. Recommend appropriate level of treatment intervention based on identified risk from screening

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0421-H1.25-UK2C

CPE
This knowledge-based activity will award 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Other
UK Healthcare CECentral certifies this activity for 1.25 hours of participation.

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.25 clinical continuing education credits.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 nursing contact hours.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

The activity was supported by Anthem.